Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering
Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...
Newsable Asianet News on MSN21h
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip
Shares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after ...
Leerink Partners Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $6.00
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...
Recursion Pharmaceuticals price target lowered to $6 from $7 at Leerink
Leerink lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Market Perform rating on the shares after ...
Spotlight on Recursion Pharmaceuticals: Analyzing the Surge in Options Activity
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...
ETF Daily News2d
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down After Earnings Miss
Recursion Pharmaceuticals shares last traded at $7.25, with a volume of 11,698,781 shares. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates ...
Seeking Alpha3d
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
Recursion Pharmaceuticals showcased significant progress in advancing its pipeline and platform capabilities, supported by clinical data readouts and partnerships with Roche and Sanofi.